PMID- 9142180
OWN - NLM
STAT- MEDLINE
DCOM- 19970520
LR  - 20220330
IS  - 0022-4790 (Print)
IS  - 0022-4790 (Linking)
VI  - 64
IP  - 4
DP  - 1997 Apr
TI  - Roles of the transforming growth factor beta 1 and its type I and II receptors in 
      the development of a pulmonary adenocarcinoma: results of an immunohistochemical 
      study.
PG  - 262-7
AB  - BACKGROUND: In the United States, pulmonary adenocarcinomas have recently 
      replaced squamous cell carcinomas as the most frequent type of lung cancer 
      encountered. The incidence of pulmonary adenocarcinoma continued to increase 
      worldwide. METHOD: To determine the roles of the transforming growth factor-beta 
      1 (TGF-beta 1), and TGF-beta type I receptor (T beta R-I), and the TGF-beta type 
      II receptor (T beta R-II) in the progression of a pulmonary adenocarcinoma, their 
      respective expressions have been immunohistologically studied in specimens from 
      120 pulmonary adenocarcinoma patients. RESULT: The overall prognosis was 
      significantly poorer for patients showing positive TGF-beta 1, T beta R-I, T beta 
      R-II expressions than for patients who were negative to all three immunostainings 
      (P < 0.01). Our multivariate analysis also revealed that a positive TGF-beta 1 
      response significantly affect prognosis (P < 0.05). CONCLUSIONS: TGF-beta 1, T 
      beta R-I, and T beta R-II play important roles in tumor progression, and a 
      positive TGF-beta 1 expression can serve as a pulmonary adenocarcinoma marker. T 
      beta R-I and T beta R-II expressions are necessary for TGF-beta signal 
      transduction.
FAU - Takanami, I
AU  - Takanami I
AD  - First Department of Surgery, Taikyo University School of Medicine, Tokyo, Japan.
FAU - Tanaka, F
AU  - Tanaka F
FAU - Hashizume, T
AU  - Hashizume T
FAU - Kodaira, S
AU  - Kodaira S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (Receptors, Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.30 (Activin Receptors, Type I)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II)
SB  - IM
MH  - *Activin Receptors, Type I
MH  - Adenocarcinoma/*chemistry/mortality/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*chemistry/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/metabolism/*physiology
MH  - Receptor, Transforming Growth Factor-beta Type I
MH  - Receptor, Transforming Growth Factor-beta Type II
MH  - Receptors, Transforming Growth Factor beta/metabolism/*physiology
MH  - Survival Rate
MH  - Transforming Growth Factor beta/metabolism/*physiology
EDAT- 1997/04/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1002/(SICI)1096-9098(199704)64:4<262::AID-JSO3>3.0.CO;2-7 [pii]
AID - 10.1002/(sici)1096-9098(199704)64:4<262::aid-jso3>3.0.co;2-7 [doi]
PST - ppublish
SO  - J Surg Oncol. 1997 Apr;64(4):262-7. doi: 
      10.1002/(sici)1096-9098(199704)64:4<262::aid-jso3>3.0.co;2-7.